Jeffrey A. Engelman, MD, PhD
Director, Center for Thoracic Cancers Massachusetts General Hospital Cancer Center; Associate Professor of Medicine, Harvard Medical School
Dr. Engelman is the director of thoracic oncology at the Massachusetts
General Hospital Cancer Center, the director of molecular therapeutics at the
MGH Cancer Center, the scientific director for the Termeer Center for Targeted
Therapies, and the Laurel Schwartz Professor of Oncology at Harvard Medical
School. For the past 10 years, Dr. Engelman has been instrumental in
understanding sensitivity and resistance to targeted therapies in lung cancer.
Dr. Engelman has been at the leading edge of translational research
advancing targeted therapies to benefit patients with cancer. His research
has revealed the mechanisms by which genetically defined subsets of lung cancer
acquire resistance to targeted therapies. These laboratory findings have led to
new therapeutic approaches for the treatment of EGFR and ALK cancers that have
become resistant to first line kinase inhibitors. This research has been
pivotal to the development of new therapies, including the development of
ceritinib for ALK cancers and combination therapies, such as EGFR and MET
inhibitors, to overcome resistance to EGFR inhibitors. Dr. Engelman has also
developed novel therapeutic approaches for KRAS mutant lung cancer and BRAF
mutant colorectal cancer that are currently being developed in the clinic.
In his multiple leadership roles
at the MGH Cancer Center, Dr. Engelman leads the translational research programs
of the thoracic oncology team and the phase I program at the MGH Cancer Center.
These programs integrate laboratory studies, clinical trials, and comprehensive
molecular analyses of cancers to pioneer individualized therapies. His
team has also established a well-developed translational infrastructure that
has culminated in a seamless bench-to-bedside connection. His lab has
developed methods to generate early passage cell cultures from core needle
biopsies of interest that can be interrogated with high-throughput drug combination
screens to identify new therapeutic strategies. Many of these same cutting-edge
technologies are now being applied to the field of immunotherapy.